CEREB
Cerebrolysin
Not a single molecule. A mixture of low-molecular-weight peptides and free amino acids produced by enzymatic breakdown of purified porcine brain protein, which is why no formula, no molecular weight and no single chemical record appears for it anywhere on this page. Its composition is defined by its manufacturing process rather than by a structure.
Cerebrolysin has 39 registered human studies on ClinicalTrials.gov, reaching phase 4, covering 4,405 planned or enrolled participants across the 36 studies that published a figure. No FDA-approved product contains Cerebrolysin. 299 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Cerebrolysin; the registry search is fuzzy, so every match is re-checked. None of this says whether Cerebrolysin works or is safe.
FDA status
Research only
Human studies
39
Furthest phase
Phase 4
Papers, 10 yr
299
Readership
3,642
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Reached phase 3 or 4, not approved
39
Registered human studies
Phase 4
Furthest phase reached
4,405
Planned or enrolled participants, across 36 studies that published a figure
None
No FDA-approved product contains it
42 loose registry matches were checked and 39 confirmed — 3 named something else and were discarded. We count a study only when Cerebrolysin is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Cerebrolysin is, and what it has been studied for
Cerebrolysin is tracked here. Its FDA substance identifier is 37KZM6S21G.
Across 39 registered trials, it has been studied in Stroke, Acute Ischemic Stroke, Ischemic Stroke and Hemorrhagic Stroke. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Ever Neuro Pharma GmbH and Ain Shams University among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Cerebrolysin reached Phase 4 across 39 registered trials.
No FDA-approved product contains Cerebrolysin. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying Cerebrolysin?
Papers published each year that name Cerebrolysin in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 31 | 0 | Yes |
| 2018 | 24 | 1 | Yes |
| 2019 | 36 | 0 | Yes |
| 2020 | 30 | 2 | Yes |
| 2021 | 32 | 5 | Yes |
| 2022 | 22 | 1 | Yes |
| 2023 | 43 | 7 | Yes |
| 2024 | 35 | 3 | Yes |
| 2025 | 47 | 2 | Yes |
| 2026 | 21 | 0 | No |
299 papers and 21 registered trials between 2017 and 2026. A paper counts when “Cerebrolysin” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Cerebrolysin
299 indexed papers name Cerebrolysin in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Cerebrolysin for acute ischaemic stroke
- Cerebrolysin for vascular dementia
- Cerebrolysin for acute ischaemic stroke
- Cerebrolysin for acute ischaemic stroke
- Cerebrolysin for acute ischaemic stroke
- Cerebrolysin for vascular dementia
- Cerebrolysin peptides as mood stabilizers
- Cerebrolysin for acute ischaemic stroke
Collected 2026-08-02from PubMed, phrase-matched on “Cerebrolysin” in title and abstract. Run the same search.
About Cerebrolysin
Not a single molecule. A mixture of low-molecular-weight peptides and free amino acids produced by enzymatic breakdown of purified porcine brain protein, which is why no formula, no molecular weight and no single chemical record appears for it anywhere on this page. Its composition is defined by its manufacturing process rather than by a structure.
- Also known as
- FPF-1070
- Source
- gsrs.ncats.nih.gov ↗
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.